Stockscreener 앱 받기
14.13
9.20%
1.19
시간 외 거래:
14.47
0.34
+2.41%
전일 마감가:
$12.94
열려 있는:
$12.88
하루 거래량:
100.62K
Relative Volume:
0.36
시가총액:
$70.17M
수익:
-
순이익/손실:
$-12.49M
주가수익비율:
-4.7659
EPS:
-2.9648
순현금흐름:
$-5.93M
1주 성능:
+23.19%
1개월 성능:
+54.93%
6개월 성능:
-2.15%
1년 성능:
+80.46%
1일 변동 폭
$12.88
$14.43
1주일 범위
$10.90
$14.43
52주 변동 폭
$6.34
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
14.13 | 64.26M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - Stock Traders Daily
INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews
Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan
Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily
INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI
MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MiNK Therapeutics, Inc. (INKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - geneonline.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - Investing News Network
HC Wainwright Issues Positive Outlook for INKT Earnings - MarketBeat
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - Sahm
MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026 - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ... - Caledonian Record
MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Cancer and ARDS data from MiNK's cell therapy heads to ASGCT - Stock Titan
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society 2026 International Conference - Investing News Network
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
MiNK Therapeutics Announces Abstract Acceptance for - GlobeNewswire
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - Investing News Network
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2025 Earnings Conference - Moomoo
MiNK Therapeutics (NASDAQ: INKT) expands iNKT trials as losses grow and going-concern risk flagged - Stock Titan
MiNK Therapeutics 2025 10-K: Net loss $(2.93) per share, $12.49M net loss - TradingView
MiNK Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
MiNK Therapeutics Reports 2025 Results and Advances Phase 2 iNKT Cell Therapy Programs for ARDS, GVHD, and Oncology - Minichart
MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
INKT: Durable clinical results, strong cash position, and major trial milestones expected in 2026 - TradingView — Track All Markets
Earnings call transcript: MiNK Therapeutics’ Q4 2025 shows cash boost amid wider losses - Investing.com India
MiNK Therapeutics Q4 Earnings Call Highlights - MarketBeat
MiNK Therapeutics (NASDAQ: INKT) details 2025 loss and cash runway into 2026 - Stock Titan
MiNK Therapeutics Initiates Phase 2 Trials for ARDS and GVHD, Planning Multiple Clinical Catalysts for 2026 - Quiver Quantitative
Ideas Watch: What is the target price for MiNK Therapeutics Inc stockWeekly Trade Report & Reliable Trade Execution Plans - baoquankhu1.vn
Whale Trades: Whats the fair value of MiNK Therapeutics Inc stock2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
MiNK Therapeutics pediatric cancer breakthrough sparks stock rally - MSN
Activity Recap: Is MiNK Therapeutics Inc stock heavily shorted2026 Rallies & Low Risk Growth Stock Ideas - baoquankhu1.vn
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight ... - Caledonian Record
MiNK Therapeutics clarifies status of agenT-797 combination trial discussions By Investing.com - Investing.com Australia
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations - TipRanks
Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments - TradingView
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.77%
자본화:
|
볼륨(24시간):